Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage B patients with hepatocellular carcinoma (HCC) and Child-Pugh A whereas in Child-Pugh B there is no definite evidence of benefit.
To assess the safety and efficacy of TACE during routine clinical practice in a consecutive Greek cohort of patients with unrespectable HCC.
Seventy one patients enrolled for this study (mean follow-up:24.6 months). 100 mg cisplatin, 50 mg doxorubicin and 10 ml lipiodol as well as embolic materials were used. CT-scans and blood tests were obtained prior and post-TACE. KaplanMeier method and Cox proportional hazard model were used to evaluate survival and factors affecting survival.
Survival at 1-year, 2-years, 3-years and 5-years was 73.2%, 45.4%, 33.2% and 14.9% respectively. Procedure-related mortality was 1.4%. Multivariate analysis showed lesion diameter, Child-Pugh classification, alcohol abuse, tumor response and AFP prior TACE as independent prognostic factors of survival. Patients diagnosed during surveillance had significantly better survival rates compared to those diagnosed after development of symptoms (HR = 0.58, 95%CI: 0.33-1.01, P < 0.05).
TACE is safe and efficient for unrespectable HCC. Alcohol abuse, tumor burden, response criteria, Child-Pugh and AFP prior to the session were identified as independent predictors of survival whereas, adherence to surveillance programs resulted in significantly better survival in these patients.
© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, et al. Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma. Hepat Mon. 2014;14(12):e25792. doi: https://doi.org/10.5812/hepatmon.25792
Kim M, Kim JW, Myung D, Jun C, Lee W, et al. Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter. I J Radiol. 2017;14(1):e13484. doi: https://doi.org/10.5812/iranjradiol.39515
Xia P, Xu A, Tian S, Huang H, Ouyang M, et al. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients. Hepat Mon. 2026;26(1):e168214. doi: https://doi.org/10.5812/hepatmon-168214
Zhang Q, Xu J, Xiong M, Tan Y. Transarterial Chemoembolization for Refractory Hepatocellular Carcinoma Following Anti-angiogenic Therapy Combined with Immune Checkpoint Inhibitors: A Retrospective Single-center Analysis. I J Radiol. 2023;20(2):e133070. doi: https://doi.org/10.5812/iranjradiol-133070
Azizi A, Naghyb N, Farshid P, M.Balisike E, J.Vogl T. Liver Metastases of Pancreatic Cancer: Role of Repetitive Transarterial Chemoembolization (TACE) on Tumor Response and Survival. I J Radiol. 2014;11(30th Iranian Congress of Radiology):e21438. doi: https://doi.org/10.5812/iranjradiol.21438
More by these authors
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 3 hours ago
Last Update: 8 hours ago
Last Update: 5 days ago
